UTD-1 is under clinical development by Beijing Biostar Technologies and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to GlobalData, Phase II drugs for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how UTD-1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
UTD-1 is under development for the treatment of solid tumors including head and neck cancer squamous cell carcinoma, esophageal cancer, human epidermal growth factor receptor 2 negative breast cancer (HER2- breast cancer), human epidermal growth factor receptor 2 positive breast cancer (HER2- breast cancer), gastric cancer, pancreatic cancer, bile duct cancer (cholangiocarcinoma), ovarian cancer, metastatic breast cancer non-small cell lung cancer, metastatic castration-resistant prostate cancer and solid tumors. It is a small molecule administered intravenously, orally and in the form of nano injection. It acts as microtubule stabilizing agent. The drug candidate is an epothilone analog generated by genetic manipulation of the polyketide biosynthetic gene cluster.
It was also under development for the treatment of metastatic colorectal cancer.
Beijing Biostar Technologies overview
Beijing Biostar Technologies, is a developer of biomedical technology intended to formulate innovative drugs for the treatment of cancer. The company is headquartered in China.
For a complete picture of UTD-1’s drug-specific PTSR and LoA scores, buy the report here.